GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Captor Therapeutics SA (WAR:CTX) » Definitions » Debt-to-Asset

Captor Therapeutics (WAR:CTX) Debt-to-Asset : 0.04 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Captor Therapeutics Debt-to-Asset?

Captor Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was zł2.53 Mil. Captor Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was zł1.25 Mil. Captor Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was zł97.29 Mil. Captor Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.04.


Captor Therapeutics Debt-to-Asset Historical Data

The historical data trend for Captor Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Captor Therapeutics Debt-to-Asset Chart

Captor Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial 0.41 0.48 0.06 0.06 0.04

Captor Therapeutics Quarterly Data
Dec17 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.07 0.06 0.04

Competitive Comparison of Captor Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Captor Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Captor Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Captor Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Captor Therapeutics's Debt-to-Asset falls into.



Captor Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Captor Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Captor Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Captor Therapeutics  (WAR:CTX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Captor Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Captor Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Captor Therapeutics (WAR:CTX) Business Description

Traded in Other Exchanges
Address
ul. Dunska 11, Wroclaw, POL, 54-427
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Captor Therapeutics (WAR:CTX) Headlines

No Headlines